The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.

Ladan Zand, Rajiv Kumar

Journal: Endocrinology and metabolism clinics of North America 2018;46(4):983-1007

PMID: 29080646

Free Full Text on PubMed Central View on PubMed

Abstract

Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance. Treatment with 1-hydroxylated vitamin D analogues is useful.

Address: Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA. Electronic address: [email protected].; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA. Electronic address: [email protected].

DOI: 10.1016/j.ecl.2017.07.008

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/kidneyfailure.html

Other Literature Sources:

https://scite.ai/reports/29080646

Subscription / membership required

Full Text Sources:

MeSH Terms: Calcitriol, Ergocalciferols, Humans, Hydroxycholecalciferols, Hyperparathyroidism, Kidney Failure, Chronic, Renal Insufficiency, Chronic, Treatment Outcome